JP2009518415A - 疾患の処置のための方法および組成物 - Google Patents

疾患の処置のための方法および組成物 Download PDF

Info

Publication number
JP2009518415A
JP2009518415A JP2008544453A JP2008544453A JP2009518415A JP 2009518415 A JP2009518415 A JP 2009518415A JP 2008544453 A JP2008544453 A JP 2008544453A JP 2008544453 A JP2008544453 A JP 2008544453A JP 2009518415 A JP2009518415 A JP 2009518415A
Authority
JP
Japan
Prior art keywords
acid
vascular
polymorph
disease
erythro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008544453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518415A5 (https=
Inventor
ダニエル アイ． オッペンハイマー，
エミール ディー． カッキス，
アレハンドロ ドレンボーム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2009518415A publication Critical patent/JP2009518415A/ja
Publication of JP2009518415A5 publication Critical patent/JP2009518415A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008544453A 2005-12-05 2006-12-05 疾患の処置のための方法および組成物 Withdrawn JP2009518415A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74257805P 2005-12-05 2005-12-05
US76497906P 2006-02-03 2006-02-03
US81784706P 2006-06-30 2006-06-30
PCT/US2006/046449 WO2007067570A1 (en) 2005-12-05 2006-12-05 Methods and compositions for the treatment of disease

Publications (2)

Publication Number Publication Date
JP2009518415A true JP2009518415A (ja) 2009-05-07
JP2009518415A5 JP2009518415A5 (https=) 2011-01-27

Family

ID=37877059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544453A Withdrawn JP2009518415A (ja) 2005-12-05 2006-12-05 疾患の処置のための方法および組成物

Country Status (6)

Country Link
US (1) US20090018136A1 (https=)
EP (1) EP1965803A1 (https=)
JP (1) JP2009518415A (https=)
AU (1) AU2006321942A1 (https=)
CA (1) CA2631740A1 (https=)
WO (1) WO2007067570A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529113A (ja) * 2007-06-09 2010-08-26 ドン・ア・ファーム・カンパニー・リミテッド ピラゾロピリミジノン誘導体化合物を含む慢性心不全治療用医薬組成物
JP2020068734A (ja) * 2018-11-01 2020-05-07 国立大学法人東京工業大学 Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
CA2755069A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011019399A1 (en) * 2009-08-13 2011-02-17 Medstar Health Research Institute, Inc. Preservation of blood vessels using phosphodiesterase inhibitors
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
HK1203420A1 (en) * 2012-07-19 2015-10-30 Vifor (International) Ltd. Compositions comprising crosslinked cation-binding polymers
WO2015006465A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
CN104530054B (zh) * 2014-12-19 2018-01-19 扬子江药业集团有限公司 盐酸优克那非的多晶型物及其制备方法
WO2021009091A1 (en) * 2019-07-15 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and treating cardiac dysfunction
WO2022173818A1 (en) * 2021-02-09 2022-08-18 University Of Virginia Patent Foundation Use of biliverdin reductase b inhibitors to allow malaria eradication in patients with g6pd deficiency

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2601215A (en) * 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US3505329A (en) * 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
JPS5883691A (ja) * 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
US5196533A (en) * 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) * 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) * 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja) * 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) * 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
US4713454A (en) * 1985-01-28 1987-12-15 Shiratori Pharmaceutical Co., Ltd. Preparation process of (6R)-tetrahydro-L-biopterin
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US4937342A (en) * 1987-11-30 1990-06-26 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing BH4 and its derivatives
JP2534423B2 (ja) * 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4308739C1 (de) * 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) * 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
ATE218345T1 (de) * 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
US20020076782A1 (en) * 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
JP4306825B2 (ja) * 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
US6200758B1 (en) * 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
EP1175210A4 (en) * 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE0000307D0 (sv) * 2000-01-31 2000-01-31 Univ Zuerich Method and formulation för treatment of vasoconstriction
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US20030007961A1 (en) * 2001-06-22 2003-01-09 Wilburn Michael D. Orthomolecular vitamin E derivatives
US20030078231A1 (en) * 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US6685458B2 (en) * 2001-10-11 2004-02-03 Acushnet Company Split metal die assembly with injection cycle monitor
WO2005018620A2 (en) * 2003-08-26 2005-03-03 Cell Center Cologne Gmbh Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
CA2588994A1 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
TW200719896A (en) * 2005-04-18 2007-06-01 Astrazeneca Ab Combination product
JP2008540486A (ja) * 2005-05-11 2008-11-20 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010529113A (ja) * 2007-06-09 2010-08-26 ドン・ア・ファーム・カンパニー・リミテッド ピラゾロピリミジノン誘導体化合物を含む慢性心不全治療用医薬組成物
JP2020068734A (ja) * 2018-11-01 2020-05-07 国立大学法人東京工業大学 Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物
JP2023041849A (ja) * 2018-11-01 2023-03-24 宏 一瀬 Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物
JP7553906B2 (ja) 2018-11-01 2024-09-19 宏 一瀬 Ｓｐｒをコードするポリヌクレオチドを含む組換えベクター、及びそれを含む組成物

Also Published As

Publication number Publication date
US20090018136A1 (en) 2009-01-15
CA2631740A1 (en) 2007-06-14
AU2006321942A1 (en) 2007-06-14
WO2007067570A1 (en) 2007-06-14
EP1965803A1 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
US20090018136A1 (en) Methods and compositions for the treatment of vascular disease
ES2433476T3 (es) Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
JP2021181478A (ja) 貧血治療のための組成物及び方法
TWI542580B (zh) 治療肺高血壓的組合物及方法
JP6195561B2 (ja) 外傷出血および関連症状の治療における使用のための、アルテミシニンおよびその誘導体
JP2010523708A (ja) テトラヒドロビオプテリンを投与する方法、関連する組成物および測定方法
ES2565519T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de la enfermedad cardiovascular en gatos
EP0036145A1 (en) An orally administered drug form comprising a polar bioactive agent and an adjuvant
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
JP2021522291A (ja) 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用
JP2019534327A (ja) ｓＧＣ刺激薬による中枢神経系疾患の治療
WO2015161510A1 (en) Saa derivative compound restores enos and inhibits oxidative stress-induced diseases in hypoxia
JP2018520151A (ja) 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用
JP6144775B2 (ja) 腎臓病の治療に使用されるアーテミシニンおよびその誘導体
JP2008523090A (ja) 新生児肺高血圧症の治療のための方法および組成物
US20150306107A1 (en) SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
CN116490177B (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
JP2020535211A (ja) 医療用葉酸塩
HK1259616A1 (zh) 用於治疗急性肾衰竭的安贝生坦
CN101365452A (zh) 治疗疾病的方法和组合物
ES2886045T3 (es) Sarpogrelato para su uso en un método para el tratamiento de cardiopatías en mamíferos
HK1126986A (zh) 治療疾病的方法和組合物
CN117915917A (zh) 使用sGC刺激剂的CNS疾病治疗
TW200808320A (en) Use of folates for the prevention and treatment of vascular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091112

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110324

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110405